PubMed Health⌕ Search

Biomedical subjects

V Seltzer

Publications and source records attributed to V Seltzer.

33 records · Page 2Linked to original sources
PubMed1985

Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.

Eleven women with advanced ovarian cancer treated postoperatively with combination chemotherapy (cytoxan, hexamethylmelamine, Adriamycin, and cis-platinum) had disease-free intervals of 5 to 46 months (mean: 22 months) and subsequently developed recurrent carcinoma. Each patient was then retreated with combination chemotherapy which included cis-platinum. There was a 72% response rate to retreatment (36% complete, 36% partial). These overall and complete remission rates are comparable to those of platinum-based combination chemotherapy in patients without prior treatment. Those patients who responded to retreatment had a significantly longer mean survival rate than those who did not.

Adult↗
PubMed1985

Effective multimodality treatment for advanced epidermoid carcinoma of the female genital tract.

Fifteen patients with advanced or recurrent squamous-cell carcinoma of the cervix, vulva, vagina, and urethra were treated with simultaneous combination chemotherapy (5-fluorouracil infusion and mitomycin C) and radiotherapy (3,000 rad for a period of three weeks). Three to four weeks after completion of radiotherapy, 13 of 15 patients achieved partial or complete tumor shrinkage. Nine of 15 patients are alive, eight of whom (at a median follow-up time of 24 months) have no evidence of disease. The longest survival time was 45 + months. There was minimal toxicity associated with this therapy. The results of this pilot study suggest that the simultaneous administration of radiation and chemotherapy is an effective method of treatment of advanced female genital tract carcinoma.

Adult↗
PubMed1984

"Second-effort" surgical resection for bulky ovarian cancer.

Eighteen women with bulky ovarian cancer at the start of chemotherapy were brought to second laparotomy after 6 months of combination chemotherapy in an effort to resect previously unresectable tumor masses. Only one of 18 had significant resection of bulk tumor such that no gross tumor was remaining, although 8 of 15 had the residual uterus removed and 6 of 10 had resection of residual ovary or ovaries. Failure to resect tumor was due to absence of any gross tumor (33%), presence of myriad small seedlings not amenable to resection (22%), or massive residual tumor (18%). Partial resection was accomplished in 22%, but all relapsed promptly in spite of continued aggressive therapy with drugs and whole abdominal irradiation. It is concluded that 6-month "second-effort" surgical resection is unlikely to benefit many women with bulky ovarian cancer, and that surgical resection must be attempted early in the course of the disease if it is to be effective.

Adult↗
PubMed1984

Sister Joseph's nodule: seven cases of umbilical metastases from gynecologic malignancies.

Seven cases of patients with gynecologic cancer and Sister Joseph's nodule, umbilical metastases from intraabdominal malignancy, are presented, making a total of 44 such cases in the literature. One such case, uterine leiomyosarcoma with umbilical metastases, is the first such lesion reported. Although the prognosis is generally poor, a few long-term survivors have been reported, and aggressive therapy may be warranted, particularly in patients with ovarian malignancy.

Adult↗
PubMed1984

Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma.

Adriamycin (50 mg/m2) and cis-diamminedichloroplatinum (50 mg/m2) were administered every 21 days to treat metastatic endometrial adenocarcinoma. This regimen resulted in three responses (one complete and two partial) in nine women (33%). Most patients had moderate or severe hematologic and gastrointestinal toxicity. One patient experienced moderate neurotoxicity. This combination of drugs did not appear effective in the treatment of recurrent endometrial adenocarcinoma, but may have a role in the therapy of primary widespread disease.

Adenocarcinoma↗
PubMed1983

Natural cytotoxicity in malignant and premalignant cervical neoplasia and enhancement of cytotoxicity with interferon.

Natural cytotoxicity was measured in 70 women with cervical dysplasia or invasive cervical cancer and in 13 controls, using a short-term chromium release assay. A significant diminution in mean cytotoxicity was found in women with CIN III and with advanced cervical carcinoma. When the peripheral blood leukocytes of patients and controls were pretreated with interferon, there was significant enhancement of the mean cytotoxicity for all groups except those with advanced cervical carcinoma (stage IIB or worse). Our results have shown a significant defect in a potentially important immune surveillance mechanism in a group of patients with premalignant disease at risk for the development of invasive cancer. A possible role for interferon in the treatment of cervical intraepithelial neoplasia is suggested.

Adult↗
PubMed1983

Psammoma bodies in papillary adenocarcinoma of the endocervix.

Psammoma bodies have never previously been noted in conjunction with cervical cancer. This paper presents a case of endocervical adenocarcinoma with psammoma bodies. Malignant and benign lesions which have previously been associated with psammoma bodies are reviewed. The proposed mechanisms of psammoma body formation are considered. The appropriate action upon finding psammoma bodies on cervicovaginal cytology is discussed.

Adenocarcinoma, Papillary↗
PubMed1982

Dianhydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix.

Eighteen evaluable patients with squamous cancer of the uterine cervix recurrent after radiation therapy or with distant metastases were treated with dianhydrogalactitol (150 mg/m2) and cisplatin (DDP) (50 mg/m2), both given iv every 3 weeks. Only 39% of the patients responded, a result no better than that previously reported for DDP alone and only one-half as good as that previously reported by our group for a combination of this drug with mitomycin, vincristine, and bleomycin. Responses lasted a median of only 5 months. Hematologic toxicity was life-threatening in 22% of the patients and was severe in all but 11% of the remaining patients. We conclude that the addition of substantial and toxic doses of dianhydrogalactitol to DDP failed to substantially enhance the rate, quality, or duration of response compared to DDP alone.

Aged↗
PubMed1979

The association of parity and marital status with the development of ovarian carcinoma: clinical implications.

Three hundred twenty-seven patients with ovarian carcinoma were compared with matched controls to determine the association of parity and marital status with the development of ovarian cancer. Nulliparous women were found to have 2.31 times the risk of developing ovarian cancer as parous women. Unmarried women had 3 times the risk of developing ovarian cancer, but marital status was not established as a variable independent of parity. Almost 8% of patients with ovarian carcinoma had had hysterectomies when they were over 40 years of age. This study indicates that parity is an important consideration when determining whether a patient is at high risk for the development of ovarian carcinoma. Other epidemiologic variables are discussed in an effort to facilitate the judicious selection of patients for elective oophorectomy at the time of hysterectomy.

Adult↗